SRCIN1: A Protein with Potential as A Drug Target and Biomarker

Target Name: SRCIN1

NCBI ID: G80725

SRCIN1

SRCIN1: A Protein with Potential as A Drug Target and Biomarker

SRCIN1 (KiAA1684) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the kilon protein family, which is a family of transmembrane proteins that are involved in various signaling pathways.

One of the unique features of SRCIN1 is its ability to interact with several different proteins, including the transcription factor p53. This interaction between SRCIN1 and p53 allows for the regulation of various cellular processes, including cell growth, apoptosis, and inflammation.

SRCIN1 has also been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that high levels of SRCIN1 are associated with poor prognosis in patients with pancreatic cancer. Additionally, SRCIN1 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer.

Due to its involvement in various signaling pathways and its association with various diseases, SRCIN1 has become a promising drug target for researchers. Studies have shown that inhibiting SRCIN1 activity has the potential to be an effective treatment for various diseases, including cancer.

One approach to inhibiting SRCIN1 activity is through the use of small molecules, such as inhibitors of the kilkinase (KIK) signaling pathway. The KIK signaling pathway is involved in various cellular processes, including cell growth, apoptosis, and inflammation. By inhibiting the activity of KIK, researchers can reduce the level of SRCIN1 in cells, which can lead to the inhibition of cellular processes that are regulated by SRCIN1.

Another approach to inhibiting SRCIN1 activity is through the use of antibodies that specifically target SRCIN1. These antibodies can be used to block the interaction between SRCIN1 and various proteins, including p53. By blocking this interaction, researchers can reduce the level of SRCIN1 in cells, which can lead to the inhibition of cellular processes that are regulated by SRCIN1.

In addition to its potential as a drug target, SRCIN1 is also a potential biomarker for various diseases. The kilon family of proteins, including SRCIN1, have been shown to be involved in various signaling pathways that are involved in the development and progression of various diseases. Therefore, measuring the level of SRCIN1 in cells or fluids, such as blood or urine, can be a potential diagnostic or predictive marker for various diseases.

Overall, SRCIN1 is a protein that has significant potential as a drug target and biomarker. Its interaction with the transcription factor p53 and its association with various diseases make it an attractive target for researchers. Further studies are needed to fully understand the role of SRCIN1 in cellular processes and its potential as a drug and biomarker.

Protein Name: SRC Kinase Signaling Inhibitor 1

Functions: Acts as a negative regulator of SRC by activating CSK which inhibits SRC activity and downstream signaling, leading to impaired cell spreading and migration. Regulates dendritic spine morphology. Involved in calcium-dependent exocytosis. May play a role in neurotransmitter release or synapse maintenance

The "SRCIN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SRCIN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets